- Exicure to Receive $25 Million Upfront Payment and Up to $725 Million in potential Milestones - Exicure to Host Conference Call Today at 8:30am ET/7:30am CT CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure, Inc., (XCUR) a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced that Allergan’s… Read More..
CHICAGO & CAMBRIDGE, Mass.-- (BUSINESS WIRE) --Exicure, Inc. (XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced that David Giljohann, chief executive officer Exicure, Inc. (XCUR), has been named to Crain’s Chicago Business magazine’s 2019 Class of “40 Under 40.” Crain’s “40… Read More..
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Growth Metrics Accelerating; Timing of Insurance Payments Affecting Short-term Revenue Growth Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced its financial results for the third… Read More..